# Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS)

> **NCT04609943** · PHASE1 · TERMINATED · sponsor: **Bayer** · enrollment: 16 (actual)

## Conditions studied

- Acute Respiratory Distress Syndrome

## Interventions

- **DRUG:** BAY1211163

## Key facts

- **NCT ID:** NCT04609943
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-24
- **Primary completion:** 2023-08-17
- **Final completion:** 2023-09-14
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Company Decision.
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04609943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04609943, "Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04609943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*